Heineken Reveals Worries over Weight-Loss Drugs and Sales
Heineken said 10 million people used GLP-1 drugs in the United States last year and urged pubs to sell smaller serves and low-alcohol drinks.
- Heineken urged British pubs to adapt to rising GLP-1 weight-loss drug use or risk losing customers and revenue. A company presentation this month advised venues to promote half-pints and low-alcohol drinks to counter potential spending declines.
- Ten of 11 GLP-1 users interviewed by Reuters reported reduced drinking, citing physical discomfort or lack of desire. Some 10 million people in the US took medications like Ozempic and Wegovy last year, according to JPMorgan research.
- Beer generated nearly £14 billion of sales in British pubs and restaurants in the year to February 2026. Market research firm Circana found households with a GLP-1 user spent about 7% less on alcohol monthly, including around 13.5% less on beer.
- Heineken said, "We see some changes in consumption behaviour among users and will continue to monitor how these behaviours evolve in 2027." The brewer noted users increasingly opt for smaller serves and premium products.
- Joseph Schacht, a professor at the University of Colorado Anschutz, said the medicines could create a potential "Prozac moment" for AUD treatment, while posing a challenge for alcohol producers if broader groups of drinkers cut back.
23 Articles
23 Articles
British pubs and bars could sell less beer in the future, the brewing company Heineken fears. The reason for this is that it's supposed to be a smear shot. Heineken also has tips on what the hosts should do now.
dagelijksestandaard.nl
LONDON (ANP/RTR) - Heineken has called on British pubs to capitalize on the popularity of weight-loss drugs, as they will otherwise lose out on too much custom and revenue. In a presentation seen by news agency Reuters, the brewer acknowledges that the drugs pose a risk to the beer...
Heineken warns weight-loss drugs could hit beer sales in British pubs
Heineken HEIN.AS has urged British pubs and bars to adapt to the booming use of weight-loss drugs or risk losing customers and revenue, according to a company presentation seen by Reuters, in a rare acknowledgement from a major alcohol maker that the medicines pose a threat to beer sales. The warning comes as GLP-1 use […]
Heineken warns UK pubs: Weight-loss drugs could hit beer sales
Heineken has warned British pubs and bars that weight-loss drugs such as Ozempic and Wegovy may reduce drinking and threaten beer sales. It recommends smaller serves, low- and no-alcohol options, and food pairings as GLP-1 use grows.
Heineken warns pubs that the sale of beer and cider could be slowed down by the use of dehydration syringes. Therefore, the brewery company advises Wirten on changes.
Coverage Details
Bias Distribution
- 67% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
